{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Mem2McIDA","lastupdate":"2024-04-08T00:00:00.000Z","update_date":"2024-04-08T00:00:00.000Z","lastModified":"Dec 19, 2024","active":1,"confidence_score":89,"confidence_score_reason":"video or image, markets, not claimed","urlname":"sequentify","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$XYIbfZocpysWtNCCbIgsqZ3TKzFqYpHAYWhbFKoOuJhllpGvs7WcF0","name":"Sequentify","oneliner":"Novel Library-Prep Solutions for Next-Generation Sequencing","registrar":"516309572","website":"https://www.sequentify.com/","careerspage":"","founded_month":1,"founded_year":2021,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/69241268","instagram":""},"social":["https://www.linkedin.com/company/69241268"],"flattenedsociallinks":"https://www.linkedin.com/company/69241268","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"1-10","employees_exact":9,"patent":1,"raised":11100000,"stage":"Seed","public_stage":"Seed","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":null,"about":"Sequentify develops genomic samples processing products and technologies,  prior to sequencing hardware loading. The company aims to make targeted DNA sequencing as common, fast, and affordable as a blood test, enabling significant growth in personalized medicine. ","climatetech_description":null,"is_climatetech_relevant":null,"phone":"","country":null,"address":{"israeli":[{"id":"97663378-49f7-48c6-9746-fbceb6c651c2","city":"Rehovot","type":null,"address":"Moti Kind St 10, Rehovot, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"bfiBDGdU3IMuXjcCwHL4NpnHfUc3QFM8Il78FTJaQNiNIZKBmclwDw","date":"Jul 31, 2025","link":"https://www.prnewswire.com/il/news-releases/sequentify-appoints-dr-ravi-majeti-as-scientific-advisor-302518449.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Management Changes","round":null,"company":"Sequentify","layoffs":null,"summary":"Sequentify has announced the appointment of Dr. Ravi Majeti as a Scientific Advisor. Dr. Majeti is a renowned expert in hematologic malignancies and holds a prestigious position at Stanford University. His expertise will aid Sequentify in expanding its portfolio of hematology-focused NGS panels and promoting the adoption of its genomic testing solutions in academic and clinical settings. Sequentify, a Weizmann Institute spinoff founded in 2021, focuses on decentralized genomic sequencing, offering solutions for oncology, screening, and infectious diseases. The company aims to address industry pain points with its sample-prep and software solutions, facilitating scalable genomic testing.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["appointment","genomic testing","hematologic","sequencing","expansion"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"6j0eUeJReN87oWYI1CI1v5COuTPICjlHKPStid19ntpJNhjgppYsGl","news_summary":"/PRNewswire/ -- Sequentify is pleased to announce the appointment of Dr. Ravi Majeti, a world-renowned expert in hematologic malignancies, as Scientific...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"hjQZhKzCORAgOoYhCjuxMKRLOGr536WTYEPcihzhnx6l3Ux3pq9wVH","date":"Jun 9, 2025","link":"https://www.prnewswire.com/il/news-releases/sequentify-and-bio-molecular-systems-partner-to-release-infiniseq-myra-protocol-for-automated-ngs-library-preparation-302476327.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"collaboration","round":null,"company":"Sequentify","layoffs":null,"summary":"Sequentify and Bio Molecular Systems (BMS) have announced the release of the InfiniSeq Protocol for the Myra liquid handling system. This collaboration combines Sequentifys targeted sequencing chemistry with BMSs automation technology, enabling high-throughput library preparation. The InfiniSeq Protocol allows for the preparation of up to 96 indexed libraries in a single run, reducing hands-on time and errors. It is designed for clinical and research applications, including oncology panels. This partnership aims to decentralize genomic testing and make it more accessible. Sequentify, a Weizmann Institute spinoff, focuses on providing scalable genomic testing solutions, while BMS specializes in life sciences instrumentation.","partners":["Bio Molecular Systems"],"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["sequencing","automation","genomics","collaboration","technology"],"date_of_event":"October 2023","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Partners  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"H32Vz1JMyX2TvbNLEHlnnoEblFnJKzaeq0yZDJ44KTS0Ku8vjjUrz7","news_summary":"/PRNewswire/ -- Sequentify and Bio Molecular Systems (BMS) today announced the release of the InfiniSeq™ Protocol for the Myra® liquid handling system, now...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Ejh6zX7JLeHzQJ7yP6WfNm8icut0qsXnknjX2xXZFOjEf3lgGVmxb7","date":"Apr 17, 2025","link":"https://www.prnewswire.com/il/news-releases/sequentify-announces-research-grants-for-high-throughput-genomic-studies-302431271.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"research grants","round":null,"company":"Sequentify","layoffs":null,"summary":"Sequentify, a Weizmann Institute spinoff founded in 2021, is offering research grants to accelerate genomic studies using its scalable targeted library preparation technology. The company invites proposals from research groups conducting genomic DNA studies with human samples, focusing on areas like oncology, rare diseases, and infectious diseases. Selected applicants will receive reagents for up to 10,000 samples and access to Sequentifys analysis software. The application period is from April 5 to June 20, 2025. Sequentify aims to facilitate large-scale genomic testing by addressing industry pain points with its sample-prep and software solutions. The company is based in Rehovot, Israel, and focuses on the clinical market.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["genomic studies","library preparation","targeted sequencing","research grants","population screening"],"date_of_event":"April 5 – June 20, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HxQkzzwimc4r6XiHFCoJQ08iwYWiCY3cAFA4028CE96E9cyr2hjq1E","news_summary":"/PRNewswire/ -- Sequentify is offering research grants to accelerate high-impact genomic studies through its uniquely fast, easy-to-use, and scalable targeted...","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"b0phLjLuJ0iDQxFfez0EyxXWB3sRFYJQnMiMTerlNip8krODQg7nPF","date":"Sep 16, 2024","link":"https://www.prnewswire.com/il/news-releases/sheba-medical-center-to-utilize-sequentifys-infiniseq-panel-in-study-to-detect-clonal-hematopoiesis-in-cancer-patients-302248928.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"partnership, study","company":"Sequentify","layoffs":"","summary":"Sequentify has partnered with Sheba Medical Centers Hematology Laboratory and other leading clinicians to conduct a joint study using Sequentifys InfiniSeq™ Myeloid Malignancies Panel. The study aims to identify Clonal Hematopoiesis of Indeterminate Potential (CHIP) in patients previously diagnosed with solid tumors, potentially advancing personalized medicine in oncology. The InfiniSeq technology offers a streamlined and cost-effective sequencing process, enhancing lab capabilities. This collaboration underscores Sheba Medical Centers commitment to diagnostic innovation and improving patient outcomes.","partners":["Sheba Medical Center","Cancer Center Institute","Maccabi Healthcare Services","Sheba Cancer Research Center"],"customers":"","investors":"","confidence":10,"key_topics":["study","partnership","oncology","sequencing","technology"],"date_of_event":"","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"","structured_issues":["Partners"],"acquisition_amount":"","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"23i1Aoo0dGnLQC5gwPmGIxx4MkzN85vMGJIctgDSyceFJFYaBbuacc","news_summary":"/PRNewswire/ -- The Hematology Laboratory, Molecular Hematology Unit, at Sheba Medical Center, Israel's largest medical center, is conducting a joint study...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"gJ5m8Qz15P8M1zB8V9ANgNBSx8IgE5NHWuyOrO8b18cP8wiaaur96F","date":"Sep 5, 2024","link":"https://www.prnewswire.com/il/news-releases/sequentify-and-dexter-collaborate-to-introduce-genomic-sequencing-solutions-to-the-romanian-market-302239224.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"partnership","company":"Sequentify","layoffs":"","summary":"Sequentify has partnered with Dexter, a Romanian distributor, to introduce its InfiniSeq™ library preparation solutions to Romania. This partnership aims to expand access to advanced genomic diagnostics in the region. The InfiniSeq protocol reduces sample preparation time significantly and is compatible with most sequencing machines, making it a practical choice for laboratories. Dexter plans to introduce additional Sequentify products, including tools for infectious disease diagnostics and oncology panels, enhancing the scope of genomic diagnostics in Romania. Sequentify is also working with other distributors across Europe to bring their products to global markets.","partners":["Dexter"],"customers":"","investors":"","confidence":9,"key_topics":["partnership","genomics","diagnostics","Romania","oncology"],"date_of_event":"","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"","structured_issues":["Partners"],"acquisition_amount":"","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"TzHwgXVw0CQcDBW0vKcZUtOuDDkqJr90OLlWXgJq5DWLQ0NWbkUUy7","news_summary":"/PRNewswire/ -- Sequentify has partnered with Dexter, a Romanian distributor, to bring Sequentify's InfiniSeq™ library preparation solutions to Romania. This...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Y801Jyex5RPFFfbqS4HMdbo8lddIVHrgOeYdrTDvy2iUXGgJAm0GTz","date":"Jan 11, 2024","link":"https://www.prnewswire.com/il/news-releases/sequentify-awarded-grant-by-israel-innovation-authority-for-infectious-disease-sequencing-panel-302031466.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Funding, Pathogen Sequencing Technology","company":"Sequentify","layoffs":"Not mentioned","summary":"Sequentify, a DNA sequencing technology company, has received funding from the Israel Innovation Authority. The grant will contribute to a $1.3 million project aimed at developing Sequentifys targeted sequencing panel for infectious disease research. The panel is intended to offer a culture-free, next-day solution for sequencing pathogens, with a focus on pathogen diagnosis and antibiotic resistance surveillance. The funding will be crucial in advancing Sequentifys research and development, and in providing timely and efficient solutions in pathogen detection.","partners":"Not mentioned","customers":"Not mentioned","investors":["Israel Innovation Authority"],"confidence":9,"key_topics":["Funding","DNA Sequencing","Infectious Disease Research","Pathogen Detection","Antibiotic Resistance Surveillance"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$1.3 million","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"AIL6X7dVb8KLA136GxYgObRBnq0LWZJAvTfGUJfF2eBxAthmqEPfkC","news_summary":"Sequentify Awarded Grant by Israel Innovation Authority for Infectious Disease Sequencing Panel","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"MY6lWjrg6fFnq1wFZodODtdQeSk27kGkdK2Gug6G5e6vdfhbmvSvzD","date":"Nov 8, 2023","link":"https://www.prnewswire.com/il/news-releases/stanford-to-use-sequentify-kits-for-hematological-malignancies-ngs-sequencing-301981511.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Partnership, Genomics, AI","company":"Sequentify","layoffs":"Not mentioned","summary":"Sequentify, a Weizmann Institute spinoff that develops synthetic biology and AI software for targeted DNA sequencing, has announced a partnership with Stanford Institute for Stem Cell Biology and Regenerative Medicine. Stanford will be using Sequentifys NGS targeted panels for acute myeloid leukemia (AML) somatic mutation detection. The partnership will aid in basic and translational research into AML pathogenesis and novel therapeutic target identification. Sequentifys InfiniSeq technology reduces sample preparation lab time and costs, making it a valuable tool for genomics research.","partners":"Stanford Institute for Stem Cell Biology and Regenerative Medicine","customers":"Stanford Institute for Stem Cell Biology and Regenerative Medicine","investors":"Not mentioned","confidence":9,"key_topics":["DNA Sequencing","Synthetic Biology","AI Software","Cancer Diagnostics","Stanford Partnership"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Partners"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"bYkxS3N7HWb1Ex6oVJcis30ezVJlbEBXCvTFoDlJ0D4JuUkFWp83sO","news_summary":"Stanford to use Sequentify kits for Hematological Malignancies NGS Sequencing","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"VebrmdP08A2ZmGLR659Wv4GkIm72HZu3rfdx9FlR1Fl3nayogClMKq","date":"Oct 31, 2022","link":"https://www.prnewswire.com/news-releases/sequentify-collaborates-with-yeda-the-commercial-arm-of-the-weizmann-institute-under-an-nih-grant-for-evaluating-the-effect-of-clonal-hematopoiesis-on-cognitive-impairment-and-kidney-function-decline-301663205.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Partnership, Research, Healthcare","company":"Sequentify","layoffs":"Not mentioned","summary":"Sequentify is collaborating with Yeda, the commercial arm of the Weizmann Institute of Science (WIS), and NIH to sequence over 6,000 patients using the Sequentify Myeloid NGS panel. The panel enables cost-effective, high throughput NGS sequencing at scale. Dr. Liran Shlush from the Weizmann Institute will use the panel to evaluate the hypothesis that age-related clonal hematopoiesis may play a role in the progression of mild cognitive impairment and kidney function decline. The panel also enables diagnostics, screening, and prediction of blood-derived cancers such as MDS, AML, MPN, CMML, and JMML.","partners":["Yeda","Weizmann Institute of Science","NIH"],"customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Collaboration","NGS Panel","Myeloid Research","InfiniSeq Technology","Healthcare"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":["Partners"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"f2prAWhhPZGwNxuYqlIhUqaXdHfyip1eP3kCJRBRfbwS6tJTs1QR1L","news_summary":"Sequentify collaborates with Yeda, the commercial arm of the Weizmann Institute, under an NIH grant for evaluating the effect of clonal hematopoiesis on cognitive impairment and kidney function decline","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0575d555-8dce-4bd2-9c03-85b953ba10c3","date":"May 10, 2022","link":"https://www.prnewswire.com/il/news-releases/democratizing-genomics-sequentify-raises-7m-to-enable-dna-sequencing-at-scale-301543513.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Investment, Growth, DNA Sequencing","company":"Sequentify","layoffs":"Not mentioned","summary":"Sequentify, a spinoff from the Weizmann Institute of Science, has raised $7 million in funding led by Israeli venture firm, OurCrowd. The company, which combines tools from synthetic biology and AI software to enable rapid targeted DNA sequencing, will use the funds to accelerate its R&D, delivery, and go-to-market plans. Sequentify has experienced a 600% revenue growth and has multiple hospitals and labs as customers. The companys products, based on its InfiniSeq proprietary platform, include COVID-19 surveillance, cancer diagnostics, and carrier screening.","partners":"Not mentioned","customers":"Multiple hospitals and labs","investors":["OurCrowd"],"confidence":9,"key_topics":["Investment","Revenue Growth","DNA Sequencing","COVID-19 Surveillance","Cancer Diagnostics"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"$7 million","structured_issues":["Investment","Customers"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"lwwNxPvgf6yhMqCph6IxQhWRe7Q6CcL9evXVwamyidTxQIgyERwRp8","news_summary":"Democratizing Genomics, Sequentify Raises $7M to Enable DNA Sequencing at Scale","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":9,"techcommunityinvolvement":null,"mediagallery":[],"tags":["genomics","diagnostics","medical-technologies","cancer","biotechnology","personalized-medicine","oncology"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IexkcoIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Released","products":["InfiniSeq"],"geomarkets":["Global"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":1,"lastfunding":"$1.3M","totalrounds":3,"fundingstage":"Seed","totalfunding":"$11.1M","publicinvestors":1,"lastpublicfunding":1300000,"totalpublicrounds":2,"totalpublicfunding":8300000},"team":[{"name":"Tom  Fleischer","email":"tom@sequentify.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4N_mx9MIDA","bounced":false,"claimed":0,"founder":1,"urlname":"tom-fleischer-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgn-_HhwoM","position":"Co-founder & CEO","last_name":"Fleischer","claimtoken":"xjTfZiKxPAiIisPWvkFKhPK2eTUgemBn4CflxYnI32impjhmPGwTer","first_name":"Tom ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/tom-fleischer/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-04-08 15:43:33.000000","initials":"TF","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Tamir Biezuner","email":"tamir@sequentify.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Jur8toJDA","bounced":false,"claimed":1,"founder":1,"urlname":"tamir-biezuner-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg-_nwjgoM","position":"Co-founder & CSO","last_name":"Biezuner","claimtoken":"bjRfzABstzQALaubgh8aoehmQmAv2m7a8chFfg3oD7VSKLIanFgnwR","first_name":"Tamir","picturekey":null,"claimeddate":"2022-11-08","linkedinurl":"https://www.linkedin.com/in/tamir-biezuner/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-11-08 09:34:04.000000","initials":"TB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Ophir Herbst","email":"","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4NuJ2bkJDA","bounced":false,"claimed":0,"founder":1,"urlname":"ophir-herbst","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgh8Ku4goM","position":"Co-founder (no longer with the comoany)","last_name":"Herbst","claimtoken":"kn7uZbaGB4P0ojnXs93Td9BjQ9QlheXflxJdEIYdrwHH9PhAUGw7Nx","first_name":"Ophir","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/ophir-herbst/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-04-08 15:43:30.000000","initials":"OH","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNqyo8cLDA","fullname":"Yotam Maman"},"biverifydate":"2021-07-27T00:00:00.000Z","crunchbaseid":"","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Jenny Sotnik-Talisman","creator_email":"genys30@yahoo.com","createdate":"2021-04-01T00:00:00.000Z","biverification":"Yotam Maman","sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"73UtkGfJBgHgxMStPh9UFADjt9ch6BcI7PilDTXlOrL62szJqpqvt9","date":"Jan 2024","amount":"$1.3M","source":"https://www.prnewswire.com/il/news-releases/sequentify-awarded-grant-by-israel-innovation-authority-for-infectious-disease-sequencing-panel-302031466.html","eventtype":"GrantEvent","granttype":1,"investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":1300000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"CoYSAZ0NbdekpplOEmXtNRiS4qq3IifNE9IbwgzBu94F5vuB74OrRI","date":"Sep 2022","amount":"$2.8M","source":"Ourcrowd's file for all their investments - Dec-2022","eventtype":"FundingRoundEvent","investment":[{"name":"OurCrowd","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/ourcrowd","logokey":"$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","tagline":null,"urlname":"/investor_page/ourcrowd","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7H-oQKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"0JXxZqrOGYA1NYLtSLzFhtNCHcEqpoDcxlTPIVJHkjLWaC2EVXrpDj","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","leadcaption":"Lead&nbsp;","followupcaption":"Follow on&nbsp;"}],"eventvisibility":"Internal","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Convertible Debt","visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='<style>\n    .visibility-tooltip-container {\n        display: flex;\n        column-gap: 0.8rem;\n        padding: 0.8rem 1rem;\n        align-items: center;\n    } \n\n    .visibility-tooltip-container text {\n        font-size: 1.4rem;\n        text-transform: capitalize;\n        font-weight: 500;\n    }\n</style>\n\n<div class=\"visibility-tooltip-container\">\n    <img height=\"20\" width=\"20\" style=\"display: none\" src=\"/assets/private-visibility.svg\"/>\n    <img height=\"20\" width=\"20\" style=\"display: flex\" src=\"/assets/internal-visibility.svg\"/>\n    <text>Internal</text>\n</div>'","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2800000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJD85anvCAw","date":"May 2022","amount":"$7M","source":"https://www.prnewswire.com/il/news-releases/democratizing-genomics-sequentify-raises-7m-to-enable-dna-sequencing-at-scale-301543513.html","eventtype":"FundingRoundEvent","investment":[{"name":"OurCrowd","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/ourcrowd","logokey":"$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","tagline":null,"urlname":"/investor_page/ourcrowd","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7H-oQKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"53189bdd-f8bb-478d-9235-5696757ba856","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","leadcaption":"Lead&nbsp;","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":7000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"1/2021","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Sequentify","logourl":"https://storage.googleapis.com/clean-finder-353810/$XYIbfZocpysWtNCCbIgsqZ3TKzFqYpHAYWhbFKoOuJhllpGvs7WcF0","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$XYIbfZocpysWtNCCbIgsqZ3TKzFqYpHAYWhbFKoOuJhllpGvs7WcF0","seoabout":"Sequentify develops genomic samples processing products and technologies,  prior to sequencing hardware loading. The company aims to make targeted DNA sequ...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":3,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Test Diagnostics & Screening","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IexkcoIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Genes","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Genes#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Test Diagnostics & Screening#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IexkcoIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Test Diagnostics & Screening#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IexkcoIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Genes#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Test Diagnostics & Screening","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Test Diagnostics & Screening"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Providers","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Genes","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Genes"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Test Diagnostics & Screening","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IexkcoIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Genes","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Test Diagnostics & Screening"],"coreTechnology":["Biologicals","Genes"],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Providers"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"CoYSAZ0NbdekpplOEmXtNRiS4qq3IifNE9IbwgzBu94F5vuB74OrRI","date":"Sep 2022","amount":"$2.8M","source":"Ourcrowd's file for all their investments - Dec-2022","eventtype":"FundingRoundEvent","investment":[{"name":"OurCrowd","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/ourcrowd","logokey":"$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","tagline":null,"urlname":"/investor_page/ourcrowd","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7H-oQKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"0JXxZqrOGYA1NYLtSLzFhtNCHcEqpoDcxlTPIVJHkjLWaC2EVXrpDj","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","leadcaption":"Lead&nbsp;","followupcaption":"Follow on&nbsp;"}],"eventvisibility":"Internal","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Convertible Debt","visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='<style>\n    .visibility-tooltip-container {\n        display: flex;\n        column-gap: 0.8rem;\n        padding: 0.8rem 1rem;\n        align-items: center;\n    } \n\n    .visibility-tooltip-container text {\n        font-size: 1.4rem;\n        text-transform: capitalize;\n        font-weight: 500;\n    }\n</style>\n\n<div class=\"visibility-tooltip-container\">\n    <img height=\"20\" width=\"20\" style=\"display: none\" src=\"/assets/private-visibility.svg\"/>\n    <img height=\"20\" width=\"20\" style=\"display: flex\" src=\"/assets/internal-visibility.svg\"/>\n    <text>Internal</text>\n</div>'","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2800000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJD85anvCAw","date":"May 2022","amount":"$7M","source":"https://www.prnewswire.com/il/news-releases/democratizing-genomics-sequentify-raises-7m-to-enable-dna-sequencing-at-scale-301543513.html","eventtype":"FundingRoundEvent","investment":[{"name":"OurCrowd","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/ourcrowd","logokey":"$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","tagline":null,"urlname":"/investor_page/ourcrowd","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7H-oQKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"53189bdd-f8bb-478d-9235-5696757ba856","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","leadcaption":"Lead&nbsp;","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":7000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"73UtkGfJBgHgxMStPh9UFADjt9ch6BcI7PilDTXlOrL62szJqpqvt9","date":"Jan 2024","amount":"$1.3M","source":"https://www.prnewswire.com/il/news-releases/sequentify-awarded-grant-by-israel-innovation-authority-for-infectious-disease-sequencing-panel-302031466.html","eventtype":"GrantEvent","granttype":1,"investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":1300000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}